See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib by Apotex is a formulation of the drug ruxolitinib, which is a kinase inhibitor used for the treatment of certain medical conditions. According to the Apotex website, ruxolitinib is specifically indicated for the treatment of patients with polycythemia vera (PV), a type of blood cancer, who have had an inadequate response to or are intolerant of hydroxyurea [1]. Additionally, ruxolitinib is also approved for the treatment of intermediate or high-risk myelofibrosis, a type of bone marrow disorder [1].

Ruxolitinib works by inhibiting the activity of Janus kinase 1 and 2 (JAK1 and JAK2), which are enzymes that play a role in the signaling of blood cell production [2]. By inhibiting these enzymes, ruxolitinib can help reduce the overproduction of blood cells that occurs in PV and myelofibrosis [2].

It is important to note that ruxolitinib can have side effects, including decreased blood cell counts, infections, and gastrointestinal symptoms [1]. Therefore, it is important for patients taking ruxolitinib to be monitored regularly by their healthcare provider.

According to DrugPatentWatch.com, ruxolitinib was first approved by the FDA in November 2011 and is currently available as a brand-name drug under the name Jakafi [3]. Apotex, a Canadian-based pharmaceutical company, manufactures and distributes a generic version of ruxolitinib [1].

In summary, ruxolitinib by Apotex is a formulation of the drug ruxolitinib, which is a kinase inhibitor used for the treatment of polycythemia vera and intermediate or high-risk myelofibrosis. It works by inhibiting the activity of JAK1 and JAK2, which are enzymes that play a role in the signaling of blood cell production. As with any medication, it is important for patients taking ruxolitinib to be monitored regularly by their healthcare provider.

Sources:

[1] Apotex. (n.d.). Ruxolitinib. Retrieved from <https://www.apotex.com/product-monograph/rx/canada/ruxolitinib-film-coated-tablets>

[2] National Cancer Institute. (2021). Ruxolitinib. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/ruxolitinib>

[3] DrugPatentWatch.com. (n.d.). Ruxolitinib. Retrieved from <https://www.drugpatentwatch.com/drugs/ruxolitinib>